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bstract
Epidemiological studies have demonstrated that diabetes mellitus (DM) is a serious health burden for both governments and healthcare providers.
yricetin, a natural flavonol with hydroxyl groups at 3, 5, 7, 3′, 4′ and 5′ positions, is commonly ingested through human diets such as fruits,
egetables, tea, berries and red wine. Although few epidemiological and clinical studies have reported the health benefits of myricetin on DM,
ncreasing evidences from in  vitro  and animal studies have confirmed its hypoglycemic effect. Importantly, myricetin has the function to ameliorate
nsulin resistance. Moreover, myricetin can execute the functions including anti-inflammation, anti-oxidative stress, anti-aldose reductase, anti-
on-enzymatic glycation and anti-hyperlipidemia. All of these functions may provide the contribution to the prevention of DM and diabetic
omplications. In this article, a comprehensive discussion to address the potential benefits of myricetin on DM and its underlying mechanisms has
een conducted.
 2012 Production and hosting by Elsevier B.V. on behalf of Beijing Academy of Food Sciences.
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.  Introduction
Diabetes mellitus (DM) is a metabolic disorder with increas-
ng prevalence all over the world. According to the International
iabetes Federation, there was approximately 366 million peo-
le suffered from DM (aged 20–79 years) in 2011 and this figure
ould climb up to 552 million by the year of 2030 [1]. All forms
f DM are characterized by hyperglycemia and the development
f diabetes-specific complications. In addition to infection and
remature death, diabetic complications include macrovascular
nd microvascular diseases such as cerebrovascular disorders,
yocardial infarction, limb amputation, blindness, renal failure,
nd a variety of debilitating neuropathies [2]. All these compli-
ations can result in disastrous consequences of economic and
ocial systems, but many synthetic drugs used today failed to
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iomplete a long-term glycemic control and alter the course of
iabetic complications. Clinically, novel treatments with fewer
ide effects are desirable for the control of DM and its compli-
ations.
Interest in the use of plant extracts that possess widespread
iological functions has increased in recent years. Myricetin
3,5,7,3′,4′,5′-hexahydroxyflavone cannabiscetin) (Fig. 1) is a
atural flavonol from fruits, vegetables, tea, berries, red wine
nd medical plants [3]. The dietary intake of myricetin from our
oods is about 0.98–1.1 mg per day, which is quite higher than
ome other flavonols [4]. Moreover, this flavonol has a unique
hemical structure. The combined contribution of hydroxyl
roups at 3, 5 positions and three continuous hydroxyl groups
t position 3′, 4′ and 5′ can increase the antioxidant effec-
iveness of myricetin, but the presence of six hydroxyl groups
an decrease its hydrophobicity, which may be the negative
actor [5,6]. Recently, the health benefits of myricetin have
een demonstrated. Apart from antioxidative and cytoprotective
ffects, anti-carcinogenic actions, antiviral and antimicrobial
roperties, and anti-platelet activity, various studies have illus-
rated that myricetin is one of hypoglycemic components from
lant sources [7–12].
.  Epidemiological  evidenceThere are some epidemiological and clinical studies related
o the myricetin on DM. Several reports state that myricetin
s associated with reduced risk of DM. It was proposed that
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nomimetic effect of myricetin were studied. Previous studiesFig. 1. Chemical structure of myricetin.
yricetin was a primitive flavonoid in Chrysobalanaceae  family
sed for traditional medicine to control the glycemia of diabetic
atients in northern Brazil [13,14]. As part of Finnish Mobile
linic Health Examination Survey, information on habitual food
onsumption from a random sample of 10,054 participants sug-
ested that the risk of type 2 diabetes mellitus (T2DM) might be
ower due to higher intake of dietary myricetin [10]. In the United
tates, researchers used a composition, including myricetin, as
n application for treating DM and metabolic disorders [15,16].
evertheless, the intake of myricetin still reveals a neutral effect.
he follow-up study (333,905 person-years) of a large cohort
f US middle-aged and older women in the Women’s Health
tudy did not provide a strong support for the hypothesis that
igh intake of myricetin could protect against the development
f T2DM (RR: 0.95; 95% CI: 0.81, 1.12; p  for trend = 0.38)
17]. These contradictory conclusions may be explained by
acial and gender differences, irrational DM and diet assessment,
nsufficient myricetin dose, short therapeutic duration, or poor
iming for supplementation initiation. Therefore, studies are still
eeded to address the pharmaceutical actions and mechanisms
f myricetin in this regard.
Although the epidemiological evidences are weak, in  vitro
nd animal studies provide the evidence in support of the
ypoglycemic effect of myricetin. In the present review, the
onnection between myricetin and DM is focused on the basis
f current studies. The underlying mechanisms have also been
iscussed, which will provide possible guidance during the treat-
ent of DM.
. In  vitro  and  animal  evidences
As mentioned above, DM is characterized by chronic hyper-
lycemia and the maintenance of normoglycemia is one of
rimary treatment goals. Increasing evidences have confirmed
hat myricetin can regulate glycemia in in  vitro  and animal stud-
es [18–20]. It was reported that myricetin could significantly
ttenuate hyperglycemia through promoting glucose uptake in
oleus muscle and liver, and enhancing hepatic glycogen syn-
hase I activity and glycogen synthesis in hepatocytes of diabetic
ats [18,19]. Moreover, myricetin might modulate glucose and
ructose transport in Xenopus  laevis  oocytes by inhibiting the
xpression of apical, or luminal, facing-facilitated glucose trans-
orter 2 (GLUT2), a major pathway of sugar absorption [20].
s a result, myricetin may inhibit or delay glucose absorp-
ion and can reveal substantial impact on the management of
h
p
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ormoglycemia. These findings not only support the hypothesis
hat myricetin can reduce hyperglycemia and ameliorate glyco-
en metabolism, but also stimulate the exploration of underlying
echanisms of myricetin on anti-diabetic function.
.1. Myricetin  and  amelioration  of  insulin  resistance  (IR)
IR is the most common etiology of DM. Improving insulin
ensitivity and ameliorating IR seem to be crucial for the
rotection of DM. In Liu’s study, repeated intravenous injection
f myricetin for 14 days was found to significantly increase
he whole-body insulin sensitivity and decrease the higher
egree of IR in fructose chow-fed rats [21]. Similar functions of
yricetin were observed in obese Zucker rats [22]. The essential
echanisms of myricetin for improving insulin sensitivity
ight be the amelioration of impaired signaling intermedi-
tes downstream of insulin receptors through enhancing the
ecretion of -endorphin, which in turn led to the activation of
eripheral -opioid receptors. Then, myricetin treatment cor-
espondingly affected the phosphorylation of insulin receptors,
nsulin receptor substrate-1 (IRS-1), the p85 regulatory subunit
f phosphatidylinositol 3-kinase, protein kinase B (PKB/Akt)
nd Akt substrate of 160 kD, with subsequent effects on glucose
ransporter 4 (GLUT4) translocation [23]. Moreover, in our
tudies, myricetin intervention also revealed the attenuation
or the inhibitory effect of hyperinsulinemia on glucose uptake
hrough increasing AMP-activated protein kinase activity in
2C12 myotubes [24]. Although further studies are still needed
o explore the mechanisms of myricetin on insulin sensitivity,
hese findings already provide a new aspect of the pharmacolog-
cal actions of myricetin, which might be used as a promising
herapeutic category for the treatment of IR and T2DM.
.2. Myricetin  and  insulinomimetic  effect
Insulin has many physiological functions including acceler-
ting glucose oxidation, promoting glucose uptake and storage
nd stimulating lipogenesis. As a compensatory adaptation to IR,
nsulin is sufficiently increased in nondiabetic subjects, whereas
n subjects with DM, the adaptation is insufficient. In addition
o the improvement of insulin sensitivity, the treatments of DM
hould also focus on the discovery of novel compounds with
nsulinomimetic effects.
Our group demonstrated a facilitated effect of myricetin on
lucose uptake in C2C12 myotubes under normal and insulin-
timulated conditions [24]. Furthermore, it was determined
hat myricetin was the only compound to stimulate lipoge-
esis and enhance insulin-stimulated lipogenesis among 30
ioflavonoids during a drug screening study. An insulinomimetic
ffect of myricetin on glucose transport in adipocytes of rats
ith non-insulin-dependent DM was also observed. The EC50
as approximately 65 mol/L [25].
Molecular mechanisms potentially contributing to the insuli-ad demonstrated that insulin could stimulate glucose trans-
ort in adipocytes through the translocation of GLUT4, in
hich tyrosine phosphorylation played a crucial role in the
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ignal-transduction pathway [26]. However, immunoblot anal-
sis of GLUT4 in rat adipocyte plasma membrane revealed
hat the stimulation of glucose transport by myricetin was not
 consequence of GLUT4 translocation. Instead, the stimula-
ion in glucose uptake was probably due to a direct interaction
f myricetin with GLUT4 [25], which was confirmed by com-
uter simulation in Strobel’s study [27]. In this study, however,
yricetin inhibited the insulin-stimulated uptake of methylglu-
ose (a substrate that enters the cells through the facilitative
exose transporter GLUT4) by adipocytes over the concentra-
ion range of 10–100 mol/L. Moreover, this flavonol could not
nhibit glucose transport by inhibiting the tyrosine kinase activ-
ty acting on IRS-1, and this characteristic further indicated a
irect interaction of myricetin with GLUT4. In conclusion, these
esults show that the effects of myricetin are still elusive, but
yricetin might directly interact with GLUT4.
.3. Myricetin  and  anti-inflammatory  effect
Inflammation is characterized by abnormal cytokine expres-
ion, increased acute phase reactants and other mediators, and
he activation of inflammatory signal pathways. A large number
f studies have linked chronic “inflammation”, or the networks
ntegral to inflammatory responses, to the development of IR
nd -cell dysfunction, which will eventually lead to DM [28].
Myricetin, as a bioactive component, was reported to
xecute the inhibitory function for the production of inflamma-
ory cytokines. In lipopolysaccharide (LPS)-stimulated primary
acrophages and RAW264.7 macrophages, myricetin could
ignificantly inhibit the production of interleukin-12 in a dose-
ependent manner via  the down-regulation of transcription
actor nuclear factor kappa-B (NF-B) binding activity [29].
yricetin was also reported to inhibit interleukin-1 (IL-1)-
nduced inflammatory mediators in SW982 human synovial
arcoma cells [30]. Moreover, in Blonska’s study, myricetin
evealed a significant reduction on IL-1  mRNA level in
AW264.7 macrophages under the stimulation of LPS and
nterferon- (IFN-), although it was no impact on the syn-
hesis and release of cytokines. However, the most potent
nhibitor of IL-1  synthesis and release in this study was chrysin,
hich decreased the concentration of IL-1  by (59.2 ±  4.2)%
n cell lysates and by (51.9 ±  1.0)% in cell-culture supernatants
P < 0.001) [31].
On the other hand, myricetin could also affect inflamma-
ory signal pathways. According to Kim’s observation, myricetin
nhibited tumor necrosis factor-  (TNF-)-induced expression
f vascular endothelial growth factor in JB6 P+ mouse epi-
ermal cells by targeting mitogen-activated protein kinase 4,
s well as MEK1 (mitogen-activated protein or extracellular
ignal-regulated kinase) [32]. In another study, the impacts
f six flavonoids on NF-B/inhibitor-B (I-B) system in
NF--activated ECV304 cells were also examined. Myricetin
ould strongly inhibit endothelial cell proliferation through
nhibiting I-B kinases [33,34]. Moreover, myricetin could
nhibit anti-Fas IgM-induced apoptosis and block the synergetic
ffect of anti-Fas IgM with TNF-  or IL-1  on cell death in
uman osteoblastic cell line MG-63. The mechanisms might be
i
a
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ssociated with the inhibition of Fas expression induced by TNF-
and IL-1, and enhancement of Fas-associated death domain
rotein-like IL-1-converting enzyme that were in the charge
f caspase-8 and caspase-3 activation [35]. Therefore, a poten-
ial application of myricetin in preventing angiogenesis-related
iseases and diabetic osteopathy might be achieved.
However, all these studies were not based on the diabetic
odels. According to the description of de Prati, myricetin
ith three hydroxyl groups in the 3′, 4′, 5′ positions of the
 ring had a strong and specific inhibitory activity on sig-
al transducer and activator of transcription 1 [36], which was
lways induced by inflammatory cytokines to reveal the harm-
ul effect on the development of DM [37–39]. In a 4-week
andomized placebo-controlled clinical trial, 300 mg blueberin
upplement (containing 50 mg myricetin) was administered in
2DM patients 3 times per day. The results showed that blue-
erin supplement significantly reduced the fasting glucose from
143 ±  5.2) mg/L to (104 ±  5.7) mg/L (P  < 0.001) in diabetic
roup, which was correlated with the reduction of serum C-
eactive protein from (5.18 ±  1.4) mg/L to (2.14 ±  1.8) mg/L
P < 0.05) [40]. Furthermore, an in  vitro  study from our labora-
ory showed that myricetin could increase cell viability, reverse
nsulin secretion, and decrease cell apoptosis under the induc-
ion of the cytokine mixture with TNF-  (10 ng/mL), IL-1
5 ng/mL) and IFN-  (1000 IU/mL) in RIN-m5f  cells [41].
herefore, myricetin may possess relevant anti-inflammatory
roperties. But so far, few researches in this area are conducted
o that the anti-inflammatory role of myricetin in diabetic models
nd the relevant mechanisms need to be further elucidated.
.4. Myricetin  and  anti-oxidative  stress
Oxidative stress, which are regulated through the balance
f reactive oxygen species (ROS) production and antioxidant
nzyme activity, play a crucial role in the pathogenesis of DM
nd its complications [42]. There was strong evidence that
yricetin could effectively remove a variety of ROS and exe-
ute the anti-oxidative activity due to a large number of active
ydroxyl groups [41,43]. It was also reported that myricetin
ould significantly reduce the increased production of free radi-
als during cell swelling and ischemic injury, and improve
xygen-glucose deprivation-induced potential decline in mito-
hondrial membrane [44]. Moreover, several studies determined
he protective effect of myricetin against ROS-induced cell
eath. For example, preincubation with flavonoids such as
yricetin, quercetin and rutin revealed significant protection on
aco-2 and HepG2 cells against hydrogen peroxide (H2O2)-
nduced DNA damage [45]. Another in  vitro  study found that
yricetin, quercetin and morin had protective effects on the apo-
tosis of cardiomyocytes induced by H2O2, which was mainly
ue to their capacity to increase Bcl-2/Bax ratio, and inhibit the
ctivation of caspase-3 [46].
Numerous studies also have evaluated the antioxidant capac-
ty of myricetin under chemical-induced environments. The
pplication of 2-deoxy-d-ribose could induce the oxidative dam-
ge of osteoblastic MC3T3-E1 cells; in contrast, myricetin
xecuted the role of anti-oxidative damage through increasing
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ell survival and decreasing the contents of MDA, protein
arbonyl and advanced oxidation protein products [47]. Simi-
arly, myricetin also suppressed the production of intracellular
OS, restore the potential of mitochondrial transmembrane,
ncrease Bcl-2/Bax ratio and decrease caspase-3 activation
n 1-methyl-4-phenylpyridinium-treated MES23.5 cells [48].
oreover, hyperactive molecules such as ROS can cover the sur-
ace of erythrocytes to result in the decrease of oxygen-carrying
bility in blood, which is correlated with diabetic complica-
ions in T2DM patients. Pandey and colleagues found that
yricetin revealed significantly protective effect on the increase
f tert-butyl hydroperoxide-induced oxidative stress parameters
ncluding malondialdehyde (MDA) and protein carbonyl group
n erythrocytes from T2DM patients (P  < 0.01) [49].
Besides ROS, reactive nitrogen species (RNS) also play a key
ole in the development of DM. Many inflammatory cytokines
nd mediators can induce the synthesis of inducible nitric oxide
ynthase (iNOS) in animals and humans with DM, resulting in
he generation of a large number of nitric oxide (NO). Several
tudies demonstrated that NO-derived peroxynitrite had obvious
oxic effects on -cells. However, myricetin could attenuate the
PS-induced outburst of iNOS gene expression and decrease
O production in intact rat liver [50]. In our study, myricetin
evealed the reduced generation of cytokine-induced NO due to
he inhibition of NF-B-dependent iNOS expression in RIN-m5f
 cells [41].
Taken together, myricetin is an effective antioxidant in in  vitro
tudies. This property might make myricetin indirectly improve
R, reduce -cell apoptosis and promote insulin secretion.
.5. Myricetin  and  anti-aldose  reductase  (AR)  effect
Glucose at high level in diabetic tissues can lead to the accu-
ulation of sorbitol via  AR pathway or polyol pathway [51],
hich plays an important role in the development of vascular
nd neurological complications [52,53]. Several studies have
evealed the improvement of retinal, renal, cardiac and neu-
onal function in diabetic patients subjected to the treatment
ith AR inhibitors. Myricetin can inhibit AR activity and might
lay an important role in the development of DM and its com-
lications [54]. For example, cultured human red blood cells in
igh glucose increased intracellular concentration of sorbitol.
owever, myricetin isolated from leaves of Anthocep  halus  chi-
ensis L  amk  at the concentration of 94.3 mol/L significantly
ecreased sorbitol level with strong inhibition of AR in eye
ens of pig (IC50: 39.7 mol/L) and rat (IC50: 15.6 mol/L)
55]. In another study, myricetin 3′,5′-dimethylether 3-O--
-glucopyranoside (10 g/mL), a derivative of myricetin, was
emonstrated as the AR inhibitory component from Nelumbo
ucifera  stamens  for the eye lens of rats with the inhibition of
nzyme activity by 40.27% [56].
.6.  Myricetin  and  anti-non-enzymatic  glycation  of  protein
ffect
Hyperglycemia, superimposed oxidative stress, and chronic
nflammatory components in diabetic tissues can cause the
a
i
e
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ccumulation of advanced glycation end products (AGEs) and
ate-stage glycoxidation adducts of proteins in multiple tissues
51], which reveals too much toxicity on cardiovascular system,
etina, kidney, peripheral limbs and other parts of the body,
eading to diabetic complications [57]. It was demonstrated that
he increased hydroxyl groups at 3′, 4′, 5, and 7 positions of
avonoids could result in strong inhibition of AGE formation
58]. Interestingly, myricetin has multiple hydroxyl groups
n these positions, which might provide a strong ability to
nhibit the generation of AGEs. Indeed, Ghaffari’s investiga-
ion found that five flavonols such as quercetin, myricetin,
aempferol, rutin and morin could decrease LDL glycation and
lectrophoretic mobility of glycated LDL in a dose-dependent
anner [59]. In another study, collagen was incubated with
lucose (250 mmol/L) in the presence of different flavonoids.
hese flavonoids (25 mol/L or 250 mol/L) markedly inhib-
ted the cross-linking formation of advanced glycation end
roducts and reduced pentosidine/hydroxyproline values in
 concentration-dependent manner. Moreover, the decreasing
nhibition order was observed from myricetin, quercetin, rutin,
+) catechin and kaempferol [60]. Therefore, myricetin is a very
otent inhibitor of AGEs, but the anti-non-enzymatic glycation
ffect of myricetin should be further studied in  vivo, especially
n diabetic models.
.7. Myricetin  and  anti-hyperlipidemia
Insulin has important regulatory effects on lipid and glu-
ose metabolism so that DM is associated with abnormal lipid
etabolism [61]. An experiment with hyperlipidemic mouse
odels fed with high-fat diet for 3 weeks demonstrated that
yricetin had a positive effect on lipid metabolism. The serum
ipids including total cholesterol, triglycerides (TG) and low
ensity lipoprotein-cholesterol (LDL-C) in hyperlipidemic mice
evealed a significant difference after the administration of
yricetin at the dose of 0.5 g/kg for 12 days when compared
ith the control group, especially the TG and LDL-C levels
p < 0.05) [62].
.8.  Myricetin  and  anti-hypertension  action
Hypertension is a common and important cardiovascular risk
actor in DM, with major implications not only for increased
orbidity and mortality, but also for healthcare costs. Sev-
ral studies based on animal models suggest that myricetin
an prevent the development of hypertension [63,64]. The
dministration of myricetin (100 mg/kg and 300 mg/kg for 6
eeks) isolated from Vitis  vinifera  Linn  (Vitaceae) was found
o reduce systolic blood pressure (SBP) and vascular reac-
ivity to catecholamines, reverse the metabolic alteration and
esult in the right shift of the cumulative concentration–response
urve of angiotensin II in fructose-induced rats [63]. In
nother study, similar functions of myricetin were observed
n deoxycorticosterone acetate (DOCA)-induced rat mod-
ls with hypertension. Chronic administration of myricetin
100 mg/kg and 300 mg/kg p.o. for 4 weeks) reduced SBP and
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ascular reactivity as well as reversed DOCA-induced heart rate
ncrease [64].
.9.  Myricetin  and  inhibition  of  human  pancreatic
-amylase  (HPA)
HPA is a key enzyme in the digestive system and catalyzes
he initial step in the hydrolysis of starch, a principal source
f glucose in human diet. Previous studies have demonstrated
hat specific inhibitors of HPA have potential for the control
f blood glucose level during the treatment process of obesity
nd DM. In order to achieve the novel inhibitors, a library with
0,000 natural biological extracts from terrestrial and marine
rigins was screened. A number of inhibitory components were
dentified, of which myricetin was a competitive inhibitor of
PA [65].
.10. Other  positive  effects
The formation of islet amyloid deposits is common in patients
ith T2DM. Although the mechanism responsible for pancreatic
 cell cytotoxicity during the process of islet amyloid formation
s still unknown, amyloid formation is considered as an impor-
ant factor in deterioration of islet function and reduction of 
ell mass [66]. Some polyphenol molecules have been demon-
trated to inhibit the formation of fibrillar assemblies and their
ssociated cytotoxicity. Hasegawa and coworkers confirmed the
nhibitory effect of several small molecules, and 12 polyphenol
ompounds, including myricetin, on the assembly of heparin-
nduced Tau protein and -amyloid1–40 into filaments [67].
urthermore, myricetin had higher binding affinity to oligomeric
nd filamentous Tau than to the monomeric form. As ther-
pies based on amyloidogenic properties were beneficial for
oth T2DM and Alzheimer’s disease, it was hypothesized that
yricetin might inhibit the formation of islet amyloid deposits.
owever, substantially more studies are highly desired for iden-
ifying the effect of myricetin on the inhibition of human islet
myloid polypeptide aggregation.
Since depression and DM are major contributors to the global
urden of diseases, the bidirectional relationship between them
s of special interest in the 21st century. Because of lack of phys-
cal activity, poor glycemic control, diabetic complications and
oor self-care, DM increased risk for depression [68]. Myricetin
as successfully applied in traditional Chinese medicine to treat
epression and anxiety [69].
. Conclusion
The rapidly increasing prevalence of DM in all parts of the
orld, coupled with increasing life expectancy, will continue
o challenge the resourcefulness of scientists and clinicians in
efining existing therapies and developing new approaches to
ontrol DM. A multitude of studies have been performed utiliz-
ng the beneficial properties of myricetin in cultured cells and
iabetic animals. Based on current results and our knowledge,
t is clear that myricetin has powerful effect at the cellular level
nd offers a great deal of promise as a novel approach for the
[man Wellness 1 (2012) 19–25 23
revention and management of DM and its complications. How-
ver, a wide diversity of questions remain open, further in  vitro
nd animal studies are still highly desired for fully understand-
ng of the identification of new molecular targets for protection
gainst DM. Moreover, randomized trials should be conducted
o determine whether myricetin can be recommended as a dietary
trategy for reducing the risk of DM development in individuals
ith high-risk diabetes or as an early treatment of DM patients.
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